XML 63 R43.htm IDEA: XBRL DOCUMENT v3.19.2
License Agreements - Additional Information (Detail)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 02, 2017
USD ($)
Nov. 17, 2016
USD ($)
Jan. 27, 2016
USD ($)
shares
Jan. 27, 2016
CAD ($)
Aug. 31, 2017
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
shares
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
shares
Jan. 27, 2016
CAD ($)
shares
License Agreement [Line Items]                        
Common stock, shares issued | shares           24,187,052   24,187,052     23,959,903  
Fair value of shares issued             $ 104,182,000          
Research and development           $ 12,267,000 7,407,000 $ 24,713,000 $ 13,054,000      
Preferred stock issued | shares           0   0     0  
UHN Agreement [Member]                        
License Agreement [Line Items]                        
Milestone fees               $ 0 0      
Annual maintenance fees               0 0      
Research and development expense           $ 132,000 0 325,000 0      
UHN Agreement [Member] | Fabry License Agreement [Member]                        
License Agreement [Line Items]                        
Option fee                       $ 20
Upfront license fee       $ 75                
Milestone payments       2,450                
UHN Agreement [Member] | Interleukin 12 License Agreement [Member]                        
License Agreement [Line Items]                        
Upfront license fee       264                
Milestone payments       19,275                
Annual maintenance fees       $ 50                
Common stock, shares issued | shares     1,161,665                 1,161,665
Fair value of shares issued     $ 480                  
Payments upon closing of an initial public offering     2,000,000                  
Fair value of derivative liability     $ 49,000                  
Research and development           $ 38,000 $ 41,000 38,000 41,000      
BioMarin Pharmaceutical Inc [Member]                        
License Agreement [Line Items]                        
Upfront license fee         $ 500,000              
Milestone payments               13,000,000        
Upfront cash payment                   $ 500,000    
Expenses related to license               0 0      
BioMarin Pharmaceutical Inc [Member] | Series B Preferred Stock [Member]                        
License Agreement [Line Items]                        
Research and development                   $ 500,000    
Preferred stock issued | shares         233,765              
GenStem Therapeutics Inc [Member]                        
License Agreement [Line Items]                        
Upfront license fee $ 1,000,000                      
Expenses related to license               0 0      
Milestone payments 16,000,000                      
Milestone payment due $ 2,000,000                      
Lund University Rights Holders Agreement [Member]                        
License Agreement [Line Items]                        
Expenses related to license               $ 0 $ 0      
Milestone payments   $ 550